Cannabinoid Therapy in Multiple Sclerosis Spasticity

Spasticity remains the strongest indication in the literature. Dosing ranges, response timelines, and monitoring.

Clinical Context

Cannabinoid evidence is moving from case series toward controlled trials. Reading that literature well avoids both premature enthusiasm and unwarranted dismissal.

What the Data Show

Reported effects depend heavily on route of administration, THC:CBD ratio, and patient profile. Comparing studies without adjusting for these variables produces fragile conclusions.

Applying It in Clinic

Start low, titrate slowly, and document response remains the most defensible practice. Structured dose-and-effect records turn clinical experience into usable data.

Bottom Line

Responsible prescribing rests on standardized product, realistic expectations, and systematic follow-up.